Amneal Pharmaceuticals, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Q3 2026 net revenue $863M (+10% YoY); adjusted EBITDA $207M (+30% YoY); adjusted diluted EPS $0.26 (+53% YoY). Company raised full-year 2026 guidance: net revenue to $3.15–$3.25B (from $3.10–$3.20B), adjusted EBITDA to $800–$815M (from $750–$780M), adjusted EPS to $1.04–$1.08 (from $0.96–$1.06). August 2026 Kashiv BioSciences acquisition funded via $350M incremental term loan; integration proceeding; net debt increased to $3.07B; net leverage 3.9x.
Why this rating
Guidance raise and strong organic growth (+10% revenue, +53% adj. EPS) are real; Kashiv acquisition ($421M cash outlay, ~$1.2B goodwill added) material but modest for $1.7B company. Leverage increase to 3.9x manageable but not negligible.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.